Annotation Detail for PLXNA3
Basic Information
Top
Pathway ID | Pathway Name |
---|
hsa04360 | Axon guidance |
Pathway ID | Pathway Name |
---|
| Axon guidance |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D016572 |
Cyclosporine |
Cyclosporine results in increased expression of PLXNA3 mRNA | increases expression | 20106945
|
D008769 |
Methylnitronitrosoguanidine |
Methylnitronitrosoguanidine results in increased expression of PLXNA3 mRNA | increases expression | 12634122
|
D013467 |
Sulindac |
Sulindac results in increased expression of PLXNA3 mRNA | increases expression | 11906190
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000008 |
Abdominal Neoplasms |
|
Sulindac |
6.36 | 14745880 |
MESH:D058186 |
Acute Kidney Injury |
|
Sulindac |
4.80 | 7897758 |
MESH:D000230 |
Adenocarcinoma |
|
Sulindac |
3.19 | 11910360 |
MESH:D000236 |
Adenoma |
|
Sulindac |
4.00 | 10223192 |
MESH:D011125 |
Adenomatous Polyposis Coli |
|
Sulindac |
5.05 | 17611924 11535846 15623613 19003578 12394442 11874996 16460482 |
MESH:D001913 |
Bowen's Disease |
|
Sulindac |
6.22 | 11207687 |
MESH:D001943 |
Breast Neoplasms |
|
Sulindac |
3.11 | 16642371 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
8.01 | 12371664 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Methylnitronitrosoguanidine |
8.01 | 2727394 |
MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.24 | 19486331 |
MESH:D003110 |
Colonic Neoplasms |
|
Sulindac |
2.97 | 12458338 12902858 |
MESH:D015179 |
Colorectal Neoplasms |
|
Sulindac |
2.69 | 11076880 10666051 11197048 18059344 |
MESH:D003930 |
Diabetic Retinopathy |
|
Sulindac |
5.76 | 17621415 12861449 |
MESH:D004715 |
Endometriosis |
|
Sulindac |
4.92 | 15652904 |
MESH:D004938 |
Esophageal Neoplasms |
|
Sulindac |
3.22 | 12235107 |
MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.34 | 19224547 |
MESH:D018221 |
Fibromatosis, Abdominal |
|
Sulindac |
6.22 | 14745880 |
MESH:D018222 |
Fibromatosis, Aggressive |
|
Sulindac |
5.87 | 19069698 |
MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.79 | 12639820 12168785 |
MESH:D005764 |
Gastroesophageal Reflux |
|
Sulindac |
5.59 | 11910360 |
MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.96 | 8708960 |
MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.16 | 15720958 |
MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.23 | 10903974 |
MESH:D007249 |
Inflammation |
|
Sulindac |
3.50 | 3291741 |
MESH:D007414 |
Intestinal Neoplasms |
|
Sulindac |
5.08 | 12584176 10223192 12351151 10213222 12628509 12663524 |
MESH:D007417 |
Intestinal Polyps |
|
Sulindac |
5.52 | 11245490 12394442 |
MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.31 | 15604871 |
MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.56 | 18776723 10903974 8314463 |
MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.12 | 12371664 |
MESH:D008105 |
Liver Cirrhosis, Biliary |
|
Sulindac |
4.47 | 12468960 |
MESH:D008107 |
Liver Diseases |
|
Sulindac |
3.11 | 14986274 16867024 |
MESH:D008175 |
Lung Neoplasms |
|
Sulindac |
2.70 | 19359593 15713900 |
MESH:D008545 |
Melanoma |
|
Sulindac |
2.87 | 16642371 |
MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.65 | 16801185 |
MESH:D053842 |
Microsatellite Instability |
|
Methylnitronitrosoguanidine |
6.63 | 17671175 |
MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.31 | 17954296 |
MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.70 | 18481113 19348381 |
MESH:D019636 |
Neurodegenerative Diseases |
|
Sulindac |
4.66 | 16850258 17266991 |
MESH:D010146 |
Pain |
|
Sulindac |
4.17 | 3291741 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Sulindac |
3.47 | 11504793 16820089 |
MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.64 | 12371664 |
MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.34 | 16882103 |
MESH:D014594 |
Uterine Neoplasms |
|
Sulindac |
5.18 | 18645019 |
MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.85 | 1336536 |
MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.31 | 17120751 |